Degrading the anaplastic lymphoma kinase protein to treat paediatric cancers
Dr Lizzie Tucker will assess a new type of treatment to fight ALK-driven childhood cancers like neuroblastoma.
Finding the best way to make two cancer-targeting T cells for the price of one
Professor John Anderson at University College London hopes to develop a cost-effective CAR T-cell combination therapy.
Investigating a new type of drug that can inhibit the growth and survival of neuroblastoma and other childhood cancers
Professor Karim Malik and Dr Jodie Bojko are testing drugs that can prevent cancer cells from making growth-promoting proteins.
Developing a new drug for the treatment of ALT-positive cancers
Dr Jon Elkins and Dr Anna Rose at the University of Oxford hope to develop a new drug which will affect vital ALT-positive cancer cell processes.
Targeting metabolism in aggressive childhood blood cancers
Prof Jonathan Bond and Dr Marie-Claire Fitzgerald aim to find a treatment that can exploit a key weakness of acute myeloid leukaemia.
Investigating the role of SET in childhood acute myeloid leukaemia to develop new treatments
Dr Maria Teresa Esposito hopes to learn more about a gene called SET in leukaemia and will test the best medicines to fight it.
Unravelling the behaviour of individual lymphoma cells to find out why the cancer can relapse or resist treatment
Professor Suzanne Turner will investigate the behaviour of individual lymphoma cells in order to find out why treatments fail.
Finding the most beneficial dose of fludarabine to optimise CAR-T therapy
Dr Shelby Barnett and Dr Geoff Shenton will monitor crucial drug levels in patients' blood in order to improve CAR T therapy protocols.
Using tiny particles in blood and cerebrospinal fluid to improve the diagnosis and treatment of childhood brain tumours
Dr Timothy Ritzmann aims to improve ependymoma care and treatment by harnessing the potential of extracellular vesicles.